Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments


Mar 2007
Agendia of Amsterdam, the Netherlands, has received market clearance from the FDA for its MammaPrint breast cancer diagnostic test. The device performs DNA microarray-based laboratory tests that measure the expression of 70 genes to predict the likelihood that the cancer will spread to another site. Information gained from the in vitro diagnostic multivariate index assays may help physicians plan follow-up treatment. The company had already been granted clearance to market the product in Europe.

AgendiaBiophotonicsDNA microarray-based laboratory testsindex assaysNews & Features

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.